Zota Health Care Ltd
Zota Health Care Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Zota Health Care Ltd Q2 FY26 key numbers
- Revenue
- Mature stores show improving monthly revenues; some already exceed INR 10 lakhs/month, with others expected to reach such levels in 2-3 years.
As stated in Zota Health Care Ltd's Q2 FY26 earnings call transcript · published 5 Aug 2026. Reported figures, not investment advice.
The short version
Consistent and stable growth track record with a meticulous approach focused on efficiency and excellence. The company is in a growth and expansion phase, opening 500-800 stores annually through FY26 and FY27, which puts pressure on profitability in the short term.
From Zota Health Care Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Consistent and stable growth track record with a meticulous approach focused on efficiency and excellence.
- Mature stores show improving monthly revenues; some already exceed INR 10 lakhs/month, with others expected to reach such levels in 2-3 years.
- Mature store average monthly revenue expected to increase from current ~INR 2.5 lakhs to INR 6.5 lakhs or more, with EBITDA margin potentially growing beyond 30%.
- Store expansion to continue aggressively, with plans to open 500-800 stores annually through FY27, driving top-line growth.
- Overall organizational revenues projected to grow steadily, with mature store revenue contribution increasing substantially by FY28, leading to improved profitability and operating leverage.
2 more points from Zota Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Zota Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is in the process of a Qualified Institutional Placement (QIP) for up to INR 500 crores, with shareholder approval already obtained and the process ongoing (Page 14).
- The primary use of the QIP funds is planned for the expansion of the Davaindia retail pharmacy business (Page 14).
- It will be shared during the public launch of QIP (Page 14).
- Post this QIP, the company expects no further fund requirements for the next 18 to 24 months (Page 14).
2 more points from Zota Health Care Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zota Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Zota Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹163 Cr, net loss ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zota Health Care Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zota Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zota Health Care Ltd Q2 FY26 results?
Consistent and stable growth track record with a meticulous approach focused on efficiency and excellence. The company is in a growth and expansion phase, opening 500-800 stores annually through FY26 and FY27, which puts pressure on profitability in the short term.
What is Zota Health Care Ltd share price analysis?
Zota Health Care Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹4,882 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zota Health Care Ltd planning capital expenditure?
The company is in the process of a Qualified Institutional Placement (QIP) for up to INR 500 crores, with shareholder approval already obtained and the process ongoing (Page 14).
Keep Zota Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.